Trial design and execution now accelerated by deep learning and data fabric capabilities.
PRINCETON, NJ June 8 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, is integrating new AI capabilities and data connectivity into its clinical trials outcome analytics platform, CODEX. The additions enable clinical trial teams to draw reliable conclusions around therapeutic safety and effectiveness, anticipate trial outcomes and plan new studies.
“Only 1 in 5,000 drugs in development will become a commercial product. One key to improving these odds lies in getting comprehensive insight for decisions. Unfortunately, the breadth of industry knowledge relating to clinical trial outcomes isn’t neatly curated and collected in a single source,” said Dr. Christopher Bouton, SVP and Head of AI at Certara. “CODEX delivers a single platform to improve this scenario, providing biopharmaceutical companies, trial sponsors and clinical research organizations with the ability to analyze and predict trial outcomes and significantly improve success rates, particularly during phase-2 and phase-3 trials where spending is at its highest.”
The CODEX platform delivers clinical trial databases with these AI novel concepts:
- Flexible Data Integration – An underlying data fabric architecture allows users to seamlessly connect multiple first, second and third-party party databases leveraging existing data storage.
- Advanced Search and Unstructured Data Analysis – Powerful deep learning, large language models and generative pre-trained transformers (GPTs) enable users to quickly query and extract insights from unstructured documents, published research and other literature-based content.
- Intuitive Interface – The intuitive CODEX Analytics App user interface streamlines the visualization and analysis of clinical outcomes data, allowing users to gain rich insights to inform drug and overall trial performance.
The CODEX platform delivers access to over 60 of Certara’s expertly curated meta-analysis databases covering clinical outcomes across therapeutic areas such as cardiovascular, central nervous system, immunology, metabolic disorders, and oncology.
The CODEX platform capabilities are based on the advanced data fabric and deep learning platform that Certara acquired with Vyasa. Vyasa Layar and associated applications are a proven solution for high-performing deep learning large language models that improve the accessibility of the structured, unstructured, and semi-structured data sources that clinical researchers rely on.
“For over 20 years, Certara’s gold-standard consulting and database development services have leveraged CODEX to enable drug development teams to better understand the clinical landscape for a given indication they are focusing on. The addition of AI and data fabric connectivity expands the capabilities of CODEX, providing our customers with a cutting-edge technology platform that maintains the quality and detail users rely on to confidently make mission-critical decisions related to their drug development pipeline,” said Jaap Mandema, Chief Innovation Officer at Certara.
Learn more about CODEX with AI capabilities: access our recent webinar: Data-Backed Trial Design– Applying AI to Clinical Outcome Analysis.
Certara（サターラ）について
サターラは、独自のバイオシミュレーションソフトウェア、技術、サービスを用いて医薬品開発を加速し、従来の創薬・医薬品開発を変革します。製薬、教育機関、規制当局のお客様 2,000人以上、6262ヵ国にてサターラの技術やサービスが活用されています。
